The Management Board opened its meeting welcoming the political agreement reached by the European Commission, the European Parliament and the Council of the European Union on the new EU pharmaceutical legislation. The legislation represents a historic milestone for European medicines regulation and for patients across the EU, creating significant opportunities to strengthen Europe’s position as a leader in pharmaceutical innovation.

The Board adopted EMA’s work programme for 2026, which sets out the Agency’s priorities for the coming year. While EMA will continue to ensure the highest standards in the evaluation and supervision of human and veterinary medicines, work during 2026 will focus on intense preparation for the changes introduced by the new EU pharmaceutical legislation, supporting innovation for public and animal health and investing in developing our staff across the European medicines regulatory network. As EMA carries out its work across these three areas, it…